# A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)

> **NCT06436742** · PHASE1 · RECRUITING · sponsor: **argenx** · enrollment: 16 (estimated)

## Conditions studied

- Congenital Myasthenic Syndrome
- CMS

## Interventions

- **BIOLOGICAL:** ARGX-119
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06436742
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-24
- **Primary completion:** 2027-08-24
- **Final completion:** 2028-01-24
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06436742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06436742, "A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06436742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*